Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cost of Revenue: 2022-2024

Historic Cost of Revenue for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Dec 2024 value amounting to $81.6 million.

  • Mirum Pharmaceuticals' Cost of Revenue rose 22.74% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $81.6 million for FY2024, which is 73.56% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Cost of Revenue stood at $81.6 million for FY2024, which was up 73.56% from $47.0 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Cost of Revenue registered a high of $81.6 million during FY2024, and its lowest value of $12.4 million during FY2022.
  • For the 3-year period, Mirum Pharmaceuticals' Cost of Revenue averaged around $47.0 million, with its median value being $47.0 million (2023).
  • Data for Mirum Pharmaceuticals' Cost of Revenue shows a peak YoY spiked of 280.14% (in 2023) over the last 5 years.
  • Mirum Pharmaceuticals' Cost of Revenue (Yearly) stood at $12.4 million in 2022, then soared by 280.14% to $47.0 million in 2023, then spiked by 73.56% to $81.6 million in 2024.